13F HOLDINGS REPORT
Versant Venture Management, LLC
Quarter ended Q4 2024 · Filed February 12, 2025 · Accession 0000950123-25-001612
Total Value
$86.7M
Positions
7
Other Managers
0
Confidential Omitted
No
Holdings (7)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Monte Rosa Therapeutics, Inc. | GLUE | 5,652,922 | $39.2M | 45.22% |
| 2 | CRISPR Therapeutics AG | CRSP | 498,558 | $19.6M | 22.62% |
| 3 | Contineum Therapeutics, Inc. | CTNM | 918,163 | $13.5M | 15.51% |
| 4 | Skye Bioscience, Inc. | SKYE | 2,007,704 | $5.7M | 6.55% |
| 5 | Repare Therapeutics, Inc. | 760273102 | 2,646,657 | $3.5M | 4.00% |
| 6 | Tempest Therapeutics, Inc. | TPST | 3,507,055 | $2.9M | 3.37% |
| 7 | Adverum Biotechnologies, Inc. | 00773U108 | 506,821 | $2.4M | 2.73% |